Quick-dissolving intraoral tablets

Drug Delivery to the Oral Cavity: Molecules to Market

Volumn , Issue , 2005, Pages 291-310

  Indiran Pather, S ^a   Khankari, Rajendra ^b   Siebert, John ^b  

^a TransOral Pharmaceuticals   (United States)

^b CIMA Labs Inc Minnesota   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84988403182     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (21)

1. Mattar ME, Markello J, Yaffe SJ. Pharmaceutic factors affecting pediatric compliance. Pediatrics 1975; 55:101-108.
2. Boreham PFL, Benrimoj S, Ong M, Craig M, Shepherd RW, Hill D, Singleton B. Aust J Hosp Pharm 1986; 16:138-142.
3. Fincham JE. Patient compliance in the ambulatory elderly: A review of the literature. J Geriatric Drug Therapy 1988; 2 (4):31-52.
4. Hurd PD, Butkovich SL. Compliance problems and the older patient: Assessing functional limitations. Drug Intell Clin Pharm 1986; 20:228-231.
5. Goldfarb J, Patel J, Wormser G. Antimicrobial flavors: A consideration in drug compliance. Drug Therapy 1986; 2:59-71.
6. Weinstein AG. Clinical management strategies to maintain drug compliance in asthmatic children. Ann Allergy Asthma Immunol 1995; 74:304-310.
7. Fennell RS, Foulkes L-M, Boggs SR. Family-based program to promote medication compliance in renal transplant children. Transplantation Proceedings 1994; 26:102-103.
8. Habib W, Khankari R, Hontz J. Fast-dissolve drug delivery systems. Crit Rev Thera Drug Carrier Syst 2000; 17:61-72.
9. Wehling F, Schuele S, Madamala N. Effervescent dosage form with microparticles. US Patent 5178878, 1993.
10. Khankari RK, Hontz J, Chastain SJ, Katzner, L. Rapidly dissolving robust dosage form. US Patent 6024981, 2000.
11. Seager H. Drug-delivery products and the Zydis® fast-dissolving dosage form. J Pharm Pharmacol 1998; 50:375-382.
12. Cooper WT. Improvements in preparing or making up medicated and other effervescing mixtures. British patent 3160.
13. Eichman JD, Robinson JR. Mechanistic studies on effervescent-induced permeability enhancement. Pharm Res 1998; 15:925-930.
14. Martin A. Physical Pharmacy. 4th ed. Philadelphia: Lea and Febiger, 1993.
15. Kietzmann D, Hahne D, Crozier TA, Weyland W, Groger P, Sonntag H. Comparison of sufentanil-propofol-anesthesia with fentanyl-propofol in major abdominal surgery. Anaesthesist 1996; 45:1151-1157.
16. Yee LY, Lopez JR. Transdermal fentanyl. Ann Pharmacother 1992; 26:1393-1399.
17. Southam MA. Transdermal fentanyl therapy: System design, pharmacokinetics and efficacy. Anticancer Drugs 1995; 6 (Suppl 3):29-34.
18. Jeal W, Benfield P. Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 1997; 53:109-138.
19. Streisand JB, Busch MA, Egan TD, Smith BG, Gay M, Pace NL. Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate. Anesthesiology 1998; 88:305-309.
20. Payne R. Factors influencing quality of life in cancer patients: The role of transdermal fentanyl in the management of pain. Semin Oncol 1998; 25 (No 3, suppl 7):47-53.
21. Claussen DS. Fentanyl citrate (fentanyl sublimaze). Gastroenterol Nurs 1993; 16:85-87.